Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Genmab A/S - American Depositary Shares (NQ:GMAB)

22.87 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	22.87
Bid (Size)	22.64 (2)
Ask (Size)	22.95 (10)
Prev. Close	22.87
Today's Range	22.87 - 22.87
52wk Range	17.23 - 28.56
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Biotech Stock With Strong Growth and Reasonable Valuation

July 01, 2025

GENMAB A/S (NASDAQ:GMAB) is a biotech stock with strong earnings growth, high profitability, and a reasonable valuation, making it a candidate for long-term investors following Peter Lynch's strategy.

Via Chartmill

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

June 15, 2025

From Genmab

Via Business Wire

Performance

YTD	+8.9%	+8.9%
1 Month	+10.6%	+10.6%
3 Month	+13.6%	+13.6%
6 Month	+9.1%	+9.1%
1 Year	-18.1%	-18.1%

More News

GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Candidate for GARP Investors

June 09, 2025

Via Chartmill

Breaking Down Genmab: 4 Analysts Share Their Views

March 11, 2025

Via Benzinga

Why Genmab Stock Smashed It on Monday

June 02, 2025

Via The Motley Fool

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

June 02, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) – A Strong Growth Stock Showing Technical Breakout Potential

May 24, 2025

Via Chartmill

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for Affordable Growth Investors

May 21, 2025

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB) - A Strong Candidate for GARP Investors

May 15, 2025

Via Chartmill

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

May 14, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals.

May 06, 2025

Via Chartmill

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

May 01, 2025

From Genmab A/S

Via Business Wire

GENMAB A/S -SP ADR (NASDAQ:GMAB): A Strong Affordable Growth Stock

May 01, 2025

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB): a strong growth stock preparing for the next leg up?.

April 29, 2025

Via Chartmill

Why Peter Lynch may take an interest in GENMAB A/S -SP ADR (NASDAQ:GMAB)

April 23, 2025

Via Chartmill

Despite its growth, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains within the realm of affordability.

April 19, 2025

Via Chartmill

Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish

April 15, 2025

Via Stocktwits

What Analysts Are Saying About Genmab Stock

April 09, 2025

Via Benzinga

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

March 31, 2025

From Genmab A/S

Via Business Wire

Does GENMAB A/S -SP ADR (NASDAQ:GMAB) match Peter Lynch’s “Invest in What You Know” philosophy?

March 28, 2025

Via Chartmill

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

March 27, 2025

Via Benzinga

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

March 27, 2025

From Genmab A/S

Via Business Wire

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

March 17, 2025

From Genmab

Via Business Wire

Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?

March 16, 2025

Via Benzinga

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?

Yes, Genmab A/S - American Depositary Shares is publicly traded.

What exchange does Genmab A/S - American Depositary Shares trade on?

Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Genmab A/S - American Depositary Shares?

The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market

What is the current price of Genmab A/S - American Depositary Shares?

The current price of Genmab A/S - American Depositary Shares is 22.87

When was Genmab A/S - American Depositary Shares last traded?

The last trade of Genmab A/S - American Depositary Shares was at 07/23/25 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.